Citations

Clear

286 citation(s) found for "Perez, Edith".

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith , Asmann, Yan W. , Eckel‐Passow, Jeanette E. , Tenner, Kathleen , Jen, Jin , Fan, Jian‐Bing , Geiger, Xochiquetzal J., McCullough, Ann E. , Chen, Beiyun, Zschunke, Michael A., Jenkins, Robert B. , Reinholz, Monica M., Kalari, Krishna R. , Dueck, Amylou C. , Sledge, George W. , Winer, Eric P. , Gralow, Julie R. , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 509-509

10.1200/jco.2014.32.15_suppl.509 Get It

Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.
Wiktor, Anne E., Meyer, Reid G., Tenner, Kathleen , Perez, Edith A. , Jenkins, Robert B. , Shah, Meera , Ballman, Karla V. , Ketterling, Rhett P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 523-523

10.1200/jco.2014.32.15_suppl.523 Get It

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-posi
Piccart, Martine , Holmes, Andrew , Baselga, José , Viale, Giuseppe , Zujewski, Jo Anne , Goldhirsch, Aron, Jackisch, Christian , Láng, István, Smith, Ian E., Boyle, Frances , Gelber, Richard D. , Perez, Edith A. , Azambuja, Evandro de , Dueck, Amylou C. , Zujewski, Jo Anne , Santillana, Sergio, Pritchard, Kathleen I. , Wolff, Antonio C. , Untch, Michael , Xu, Binghe , Gómez, Henry

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA4-LBA4

10.1200/jco.2014.32.15_suppl.lba4 Get It

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT a
Pagani, Olivia , Regan, Meredith M. , Walley, Barbara , Láng, István, Burstein, Harold J. , Perez, Edith A. , Ciruelos, Eva, Martino, Silvana, Coates, Alan S. , Gelber, Richard D. , Goldhirsch, Aron, Group, SOFT and TEXT Investigators and International Breast Cancer Study, Fleming, Gini F. , Colleoni, Marco , Gómez, Henry , Tondini, Carlo Alberto , Stearns, Vered , Bonnefoi, Hervé , Geyer, Charles E. , Rabaglio, Manuela , Francis, Prudence A. , Group, SOFT and TEXT Investigators and International Breast Cancer Study

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA1-LBA1

10.1200/jco.2014.32.15_suppl.lba1 Get It

Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Chapman, Judy‐Anne W., Burnell, Margot J., Levine, Mark N. , Whelan, Timothy J. , Albain, Kathy S. , Perez, Edith A. , Virk, Shakeel , O’Brien, Patti, Shepherd, Lois E. , Gelmon, Karen A. , Liu, Shuzhen , Pritchard, Kathleen I. , Rugo, Hope S. , Nielsen, Torsten O. , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11019-11019

10.1200/jco.2014.32.15_suppl.11019 Get It

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.
Advani, Pooja , Dockter, Travis , Colón‐Otero, Gerardo , Perez, Edith A. , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 603-603

10.1200/jco.2014.32.15_suppl.603 Get It

Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.
Spector, Neil L., Mano, Max S. , Canon, Jean-Luc, Gómez, Henry , El‐Hariry, Iman , Vukovic, Vojislav, Sheldon, Emily H, Perez, Edith A. , Cameron, David , Cortés, Javier , Canon, Jean-Luc Re , Hickish, Tamas , Vahdat, Linda T. , Kim, Sung-Bae , Awada, Ahmad

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS665-TPS665

10.1200/jco.2014.32.15_suppl.tps665 Get It

Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials.
O’Sullivan, Ciara C. , Bradbury, Ian , Perez, Edith A. , Rastogi, Priya , Spielmann, M., Costantino, Joseph P., Zardavas, Dimitrios, Piccart, Martine , Zujewski, JoAnne, Holmes, Eileen , Gelber, Richard D. , Azambuja, Evandro de , Joensuu, Heikki , Ballman, Karla V. , Delaloge, Suzette , Zujewski, Jo Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 508-508

10.1200/jco.2014.32.15_suppl.508 Get It

Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).
Chapman, Judy‐Anne W., Burnell, Margot J., Levine, Mark N. , O’Brien, Patti, Han, Lei , Albain, Kathy S. , Perez, Edith A. , Vandenberg, Theodore A. , Chalchal, Haji , Sawhney, Ravinder, Shepherd, Lois E. , Lohmann, Ana Elisa , Tsvetkova, Elena V. , Pritchard, Kathleen I. , Gelmon, Karen A. , Rugo, Hope S. , Goodwin, Pamela J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 504-504

10.1200/jco.2014.32.15_suppl.504 Get It

Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831.
Soyano, Aixa , Serie, Daniel, Mashadi-Hossein, Afshin , Warren, Sarah , Colón‐Otero, Gerardo , Knutson, Keith L. , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Thompson, E. Aubrey , Chumsri, Saranya , Soyano, Aixa , Knutson, Keith L.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 530-530

10.1200/jco.2017.35.15_suppl.530 Get It

530 Background: Therapeutic efficacy of H involves activation of the immune system.Age-dependent progressive deterioration of the immune response is referred as immunosenescence. In HER2+ breast cancer, the effects of aging and the ability of H to activate endogenous anti-tumor immunity is unknown. A previous report from HERA trial showed no significant increase in risk of early recurrence with age (≤ or > 40). We evaluated the long-term outcome of HER2+ patients (pt) related to age and immune landscape. Methods: 1,392 pt from N9831 trial were evaluated. Stromal tumor infiltrating lymphocytes (sTIL) were evaluated in H&E slides. Lymphocyte predominant breast cancer (LPBC) was defined as sTIL ≥ 50%. Molecular TIL (mTIL) and immune subset signatures were evaluated using NanoString research CodeSets. Cox proportional hazard ratio (HR) was used for analysis. Results: There were 1,111 (79.8%) pt > 40 years old (yo) and 281 (20.2%) pt ≤ 40 yo. Younger age was significantly associated with hormone receptor positivity (p 0.00011) and luminal B subtype (p 0.011). With a median follow up of 10.6 years, there was no significant difference in long-term outcome among pt ≤ 40 vs. > 40 yo who received H (HR = 0.88 (0.62-1.24), p = 0.45). Similar findings were observed when age was dichotomized at 50 and 60 yo. While there was no association between sTIL and age, a small but significant increase in mTIL CD45 expression with age (p 0.003) was observed. Similar small increases in cytotoxic cell (p 0.007) and T cell (p 0.015) immune scores were also observed with increasing age. Among pt who received chemotherapy alone, pt > 40 yo with LPBC (n 55) had excellent outcome with 92.4% recurrence free survival (RFS) at 10 years. However, there was no significant difference in RFS among pt ≤ 40 yo with or without LPBC. Conclusions: Among pt treated with H, there was no significant difference in outcome related to age. In contrast to a decline expected from immunosenescence, we observed small but significant increases in mTIL signatures for total lymphocytes, cytotoxic, and T cell subsets. Among patients who received chemotherapy alone, our data suggested that pt > 40 yo with LPBC had excellent prognosis, compared to pt > 40 yo without LPBC.